In recent years, anti-PD-L1/anti-PD-1 immune checkpoint inhibitors (ICIs) have become the standard of care for previously treated NSCLC without a targetable oncogene, and have rapidly become first-line treatment for patients with advanced NSCLC 2, 3, 8-11. Here, CD274 is linked to non-small cell lung carcinoma.